INTRODUCTION: While RARP (robotic-assisted radical prostatectomy) has become the predominant surgical approach to treat localized prostate cancer, there is little Canadian data on its oncological and functional outcomes. We describe the largest RARP experience in Canada. METHODS: Data from 722 patients who underwent RARP performed by 7 surgeons (AEH performed 288, TH 69, JBL 23, SB 17, HW 15, QT 7, and KCZ 303 patients) were collected prospectively from October 2006 to December 2013. Preoperative characteristics, as well as postoperative surgical and pathological outcomes, were collected. Functional and oncological outcomes were also assessed up to 72 months postoperative. RESULTS: The median follow-up (Q1-Q3) was 18 months (9-36). The D'Amico risk stratification distribution was 31% low, 58% intermediate and 11% high-risk. The median operative time was 178 minutes (142-205), blood loss was 200 mL (150-300) and the postoperative hospital stay was 1 day (1-23). The transfusion rate was only 1.0%. There were 0.7% major (Clavien III-IV) and 10.1% minor (Clavien I-II) postoperative complications, with no mortality. Pathologically, 445 men (70%) were stage pT2, of which 81 (18%) had a positive surgical margin (PSM). In addition, 189 patients (30%) were stage pT3 and 87 (46%) with PSM. Urinary continence (0-pads/day) returned at 3, 6, and 12 months for 68%, 80%, and 90% of patients, respectively. Overall, the potency rates (successful penetration) for all men at 6, 12, and 24 months were 37%, 52%, and 59%, respectively. Biochemical recurrence was observed in 28 patients (4.9%), and 14 patients (2.4%) were referred for early salvage radiotherapy. In total, 49 patients (8.4%) underwent radio-therapy and/or hormonal therapy. CONCLUSIONS: This study shows similar results compared to other high-volume RARP programs. Being the largest RARP experience in Canada, we report that RARP is safe with acceptable oncologic outcomes in a Canadian setting.
INTRODUCTION: While RARP (robotic-assisted radical prostatectomy) has become the predominant surgical approach to treat localized prostate cancer, there is little Canadian data on its oncological and functional outcomes. We describe the largest RARP experience in Canada. METHODS: Data from 722 patients who underwent RARP performed by 7 surgeons (AEH performed 288, TH 69, JBL 23, SB 17, HW 15, QT 7, and KCZ 303 patients) were collected prospectively from October 2006 to December 2013. Preoperative characteristics, as well as postoperative surgical and pathological outcomes, were collected. Functional and oncological outcomes were also assessed up to 72 months postoperative. RESULTS: The median follow-up (Q1-Q3) was 18 months (9-36). The D'Amico risk stratification distribution was 31% low, 58% intermediate and 11% high-risk. The median operative time was 178 minutes (142-205), blood loss was 200 mL (150-300) and the postoperative hospital stay was 1 day (1-23). The transfusion rate was only 1.0%. There were 0.7% major (Clavien III-IV) and 10.1% minor (Clavien I-II) postoperative complications, with no mortality. Pathologically, 445 men (70%) were stage pT2, of which 81 (18%) had a positive surgical margin (PSM). In addition, 189 patients (30%) were stage pT3 and 87 (46%) with PSM. Urinary continence (0-pads/day) returned at 3, 6, and 12 months for 68%, 80%, and 90% of patients, respectively. Overall, the potency rates (successful penetration) for all men at 6, 12, and 24 months were 37%, 52%, and 59%, respectively. Biochemical recurrence was observed in 28 patients (4.9%), and 14 patients (2.4%) were referred for early salvage radiotherapy. In total, 49 patients (8.4%) underwent radio-therapy and/or hormonal therapy. CONCLUSIONS: This study shows similar results compared to other high-volume RARP programs. Being the largest RARP experience in Canada, we report that RARP is safe with acceptable oncologic outcomes in a Canadian setting.
Authors: Thomas E Ahlering; David Woo; Louis Eichel; David I Lee; Robert Edwards; Douglas W Skarecky Journal: Urology Date: 2004-05 Impact factor: 2.649
Authors: Vincenzo Ficarra; Giacomo Novara; Raymond C Rosen; Walter Artibani; Peter R Carroll; Anthony Costello; Mani Menon; Francesco Montorsi; Vipul R Patel; Jens-Uwe Stolzenburg; Henk Van der Poel; Timothy G Wilson; Filiberto Zattoni; Alexandre Mottrie Journal: Eur Urol Date: 2012-06-01 Impact factor: 20.096
Authors: David F Penson; Dale McLerran; Ziding Feng; Lin Li; Peter C Albertsen; Frank D Gilliland; Ann Hamilton; Richard M Hoffman; Robert A Stephenson; Arnold L Potosky; Janet L Stanford Journal: J Urol Date: 2005-05 Impact factor: 7.450
Authors: Leslie R Schover; Rachel T Fouladi; Carla L Warneke; Leah Neese; Eric A Klein; Craig Zippe; Patrick A Kupelian Journal: Cancer Date: 2002-10-15 Impact factor: 6.860
Authors: Rafael F Coelho; Sanket Chauhan; Kenneth J Palmer; Bernardo Rocco; Manoj B Patel; Vipul R Patel Journal: BJU Int Date: 2009-10-05 Impact factor: 5.588
Authors: Antonio Benito Porcaro; Marco Sebben; Paolo Corsi; Alessandro Tafuri; Tania Processali; Marco Pirozzi; Nelia Amigoni; Riccardo Rizzetto; Giovanni Cacciamani; Arianna Mariotto; Alberto Diminutto; Matteo Brunelli; Vincenzo De Marco; Salvatore Siracusano; Walter Artibani Journal: J Robot Surg Date: 2019-04-05
Authors: Khaled Ajib; Marc Zanaty; Mansour Alnazari; Emad Rajih; Pierre-Alain Hueber; Mila Mansour; Roger Valdivieso; Cristina Negrean; Pierre I Karakiewicz; Daniel Taussky; Guila Delouya; Assaad El-Hakim; Kevin C Zorn Journal: Can Urol Assoc J Date: 2017-12-01 Impact factor: 1.862
Authors: Antonio B Porcaro; Alessandro Tafuri; Marco Sebben; Paolo Corsi; Tania Processali; Marco Pirozzi; Nelia Amigoni; Riccardo Rizzetto; Aliasger Shakir; Giovanni Cacciamani; Arianna Mariotto; Matteo Brunelli; Riccardo Bernasconi; Giovanni Novella; Vincenzo De Marco; Walter Artibani Journal: Arab J Urol Date: 2019-05-30